Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Spectral-domain Optical Coherence Tomography Findings in Retinal Vessel Occlusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03061526
Recruitment Status : Recruiting
First Posted : February 23, 2017
Last Update Posted : September 18, 2019
Sponsor:
Information provided by (Responsible Party):
Dr.med. Egbert Matthé, Technische Universität Dresden

Brief Summary:
Retinal vessel occlusions might lead to ischemia of the inner retina, more severe so in artery occlusions. Intracellular edema may develop and decrease transparency of those layers, showing retinal edema. In spectral domain optical coherence tomography (SD-OCT) retinal reflectivity changes as a result of retinal edema. The investigators examine the reflectivity changes of different retinal layers between healthy eyes and eyes with retinal artery occlusion and ischemic or non-ischemic vein occlusions. Aim of the study is to evaluate whether those changes can be used to measure the level of ischemia in the inner retina.

Condition or disease Intervention/treatment
Retinal Ischemia Other: optical coherence tomography

Detailed Description:
Several studies tried to classify retinal ischemia due to retinal artery or vein occlusion into different grades. In some cases prognosis is dependent on grade of severity, especially in cases of retinal vein occlusion. State of the art to Diagnose the severity of retinal ischemia is lfuorescein angiography. However, this technique is invasive and might cause Problems like anaphylactic shock. Optical coherence tomography is a non-invasive technique, but up to now there is no standardized method to quantify the grade of severity of retinal ischemia in such conditions like retinal vessel occlusion. The study hope to find criteria by which such a classification can be constructed.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Spectral-domain Optical Coherence Tomography Findings in Retinal Vessel Occlusion - A Pilot Study of Detecting Ischemia in OCT
Actual Study Start Date : May 1, 2017
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2021

Intervention Details:
  • Other: optical coherence tomography
    measurement of reflectivity in different retinal layers based on optical coherence tomography findings


Primary Outcome Measures :
  1. reflectivity [ Time Frame: December 2017 ]
    optical density of different retinal layers



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Chart Review of patients treated b/o retinal vessel occlusion, who were examined with optical coherence tomography
Criteria

Inclusion Criteria:

  • acute Retinal vessel occlusion on one eye
  • healthy contralateral eye
  • examined with spectral Domain optical coherence tomography

Exclusion Criteria:

  • retinal occlusion older than 1 week
  • OCT Image not obtainable/missing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03061526


Contacts
Layout table for location contacts
Contact: Egbert Matthé, MD +493514583381 egbert.matthe@uniklinikum-dresden.de
Contact: Olga Furashova

Locations
Layout table for location information
Germany
University Eye Hospital Recruiting
Dresden, Germany, 01307
Contact: Egbert Matthé, MD    +493514583381    egbert.matthe@uniklinikum-dresden.de   
Sponsors and Collaborators
Technische Universität Dresden
Investigators
Layout table for investigator information
Principal Investigator: Egbert Matthé, MD Technical University Dresden

Layout table for additonal information
Responsible Party: Dr.med. Egbert Matthé, Principal Investigator, Technische Universität Dresden
ClinicalTrials.gov Identifier: NCT03061526    
Other Study ID Numbers: EK 417102016
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: September 18, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemia
Pathologic Processes